Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:ELDN NASDAQ:SCLX NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.80+0.2%$9.31$3.75▼$11.54$158.05M2.7170,700 shs62,727 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$144.91M-0.12642,976 shs677,478 shsSCLXScilex$26.28+3.6%$15.24$3.60▼$41.30$176.40M1.34213,275 shs342,895 shsTELOTelomir Pharmaceuticals$1.36-0.7%$1.54$1.12▼$8.40$44.23M-0.734.65 million shs401,802 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+0.20%+10.11%-1.90%+4.81%+979,999,900.00%ELDNEledon Pharmaceuticals-4.72%-10.70%-6.92%-15.68%-5.47%SCLXScilex+3.63%+15.26%+25.14%+445.23%-31.11%TELOTelomir Pharmaceuticals-0.73%+9.68%-15.00%-30.61%-77.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.80+0.2%$9.31$3.75▼$11.54$158.05M2.7170,700 shs62,727 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$144.91M-0.12642,976 shs677,478 shsSCLXScilex$26.28+3.6%$15.24$3.60▼$41.30$176.40M1.34213,275 shs342,895 shsTELOTelomir Pharmaceuticals$1.36-0.7%$1.54$1.12▼$8.40$44.23M-0.734.65 million shs401,802 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+0.20%+10.11%-1.90%+4.81%+979,999,900.00%ELDNEledon Pharmaceuticals-4.72%-10.70%-6.92%-15.68%-5.47%SCLXScilex+3.63%+15.26%+25.14%+445.23%-31.11%TELOTelomir Pharmaceuticals-0.73%+9.68%-15.00%-30.61%-77.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00104.08% UpsideELDNEledon Pharmaceuticals 2.75Moderate Buy$10.00313.22% UpsideSCLXScilex 2.50Moderate Buy$455.001,631.35% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.001,002.94% UpsideCurrent Analyst Ratings BreakdownLatest TELO, ELDN, ACOG, and SCLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$9.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.05 per shareN/ASCLXScilex$56.59M3.23N/AN/A($27.68) per share-0.95TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.60N/A∞N/AN/A-80.16%-60.95%11/13/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)SCLXScilex-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.54N/AN/AN/AN/A-4,595.08%-1,750.91%11/11/2025 (Estimated)Latest TELO, ELDN, ACOG, and SCLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACOGAlpha Cognition-$0.46-$0.65-$0.19-$0.65$2.32 million$1.66 million8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/14/2025Q2 2025TELOTelomir Pharmaceuticals-$0.08-$0.17-$0.09-$0.17N/AN/A8/13/2025Q2 2025SCLXScilex-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83ELDNEledon PharmaceuticalsN/A8.128.12SCLXScilexN/A0.110.10TELOTelomir PharmaceuticalsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AELDNEledon Pharmaceuticals56.77%SCLXScilex69.67%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%ELDNEledon Pharmaceuticals12.30%SCLXScilex7.94%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.16 million13.90 millionN/AELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableSCLXScilex806.96 million6.40 millionOptionableTELOTelomir Pharmaceuticals132.28 millionN/AN/ATELO, ELDN, ACOG, and SCLX HeadlinesRecent News About These CompaniesTELO Releases Cancer Suppressing ResultsSeptember 9, 2025 | msn.comTelomir Pharmaceuticals announces preclinical cancer data on Telomir-1September 9, 2025 | msn.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor ...September 9, 2025 | charlotteobserver.comCTelomir Pharmaceuticals Unveils Promising Preclinical Cancer DataSeptember 9, 2025 | tipranks.comTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and ChemotherapySeptember 9, 2025 | accessnewswire.comATelomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest UpdateSeptember 8, 2025 | americanbankingnews.comTelomir Pharmaceuticals Completes $2.9 Million Stock SaleSeptember 4, 2025 | tipranks.comHead to Head Survey: Telomir Pharmaceuticals (NASDAQ:TELO) & 4D Molecular Therapeutics (NASDAQ:FDMT)September 2, 2025 | americanbankingnews.comTelomir stock soars after drug candidate shows promising epigenetic effectsAugust 28, 2025 | za.investing.comTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging ...August 28, 2025 | kansascity.comKTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related DiseasesAugust 28, 2025 | accessnewswire.comATELO Makes Progress Toward Human TrialsAugust 15, 2025 | msn.comTelomir-1 inhibits key histone demethylase enzymes in vitroAugust 12, 2025 | bioworld.comBTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...August 8, 2025 | kansascity.comKTelomir Flat on Trial Data ReleaseAugust 7, 2025 | baystreet.caTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic DysfunctionAugust 7, 2025 | accessnewswire.comATelomir Pharmaceuticals Announces Promising Preclinical ResultsJuly 26, 2025 | theglobeandmail.comTelomir Pharmaceuticals stock surges on promising Progeria treatment resultsJuly 25, 2025 | investing.comTELO Announces Another Important BreakthroughJuly 25, 2025 | finance.yahoo.comTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson'sJuly 24, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTELO, ELDN, ACOG, and SCLX Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.80 +0.02 (+0.20%) As of 09/12/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Eledon Pharmaceuticals NASDAQ:ELDN$2.42 -0.12 (-4.72%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.50 +0.08 (+3.31%) As of 09/12/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Scilex NASDAQ:SCLX$26.28 +0.92 (+3.63%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$26.00 -0.28 (-1.07%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.Telomir Pharmaceuticals NASDAQ:TELO$1.36 -0.01 (-0.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 09/12/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
